Literature DB >> 16192313

Ketamine produces lasting disruptions in encoding of sensory stimuli.

Christina R Maxwell1, Richard S Ehrlichman, Yuling Liang, Danielle Trief, Stephen J Kanes, Jonathan Karp, Steven J Siegel.   

Abstract

The current study analyzed the acute, chronic, and lasting effects of ketamine administration in four inbred mouse strains (C3H/HeHsd, C57BL/6Hsd, FVB/Hsd, and DBA/2Hsd) to evaluate vulnerability to ketamine as a drug of abuse and as a model of schizophrenia. Serum half-life of ketamine was similar between all strains (approximately 13 min). Also, the ratio of brain-to-serum ketamine levels was 3:1. Examination of multiple phases of auditory processing using auditory-evoked potentials (AEPs) following acute ketamine (0, 5, and 20 mg/kg) treatment revealed C3H/HeHsd mice to be most vulnerable to ketamine-induced alterations in AEPs, whereas FVB/Hsd mice exhibited the least electrophysiological sensitivity to ketamine. Overall, the precortical P1-evoked potential component increased in amplitude and latency, whereas the cortically generated N1 and P2 components decreased in amplitude and latency following acute ketamine across all strains. Brain catecholamine analyses indicated that ketamine decreased hippocampus epinephrine levels in C3H/HeHsd but elevated hippocampus epinephrine levels in FVB/Hsd, suggesting one potential mechanism for AEP vulnerability to ketamine. Based on results of the acute study, the immediate and lasting effects of chronic low-dose ketamine on AEPs were examined among C3H/HeHsd (sensitive) and FVB/Hsd (insensitive) mice. We observed a decrement of the N1 amplitude that persisted at least 1 week after the last exposure to ketamine across both strains. This lasting deficit in information processing occurred in the absence of acute changes among the FVB/Hsd mice. Implications for both ketamine abuse and N-methyl-D-aspartate hypofunction models of schizophrenia are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16192313     DOI: 10.1124/jpet.105.091199

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  61 in total

1.  CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy.

Authors:  Anita J Bechtholt-Gompf; Karen L Smith; Catherine S John; Hannah H Kang; William A Carlezon; Bruce M Cohen; Dost Ongür
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

Review 2.  Translating glutamate: from pathophysiology to treatment.

Authors:  Daniel C Javitt; Darryle Schoepp; Peter W Kalivas; Nora D Volkow; Carlos Zarate; Kalpana Merchant; Mark F Bear; Daniel Umbricht; Mihaly Hajos; William Z Potter; Chi-Ming Lee
Journal:  Sci Transl Med       Date:  2011-09-28       Impact factor: 17.956

Review 3.  Psychiatric drugs bind to classical targets within early exocytotic pathways: therapeutic effects.

Authors:  Henry A Lester; Julie M Miwa; Rahul Srinivasan
Journal:  Biol Psychiatry       Date:  2012-07-06       Impact factor: 13.382

4.  Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways.

Authors:  Ji-Woon Kim; Lisa M Monteggia
Journal:  Behav Brain Res       Date:  2019-11-21       Impact factor: 3.332

5.  Different serotonin receptor agonists have distinct effects on sound-evoked responses in inferior colliculus.

Authors:  Laura M Hurley
Journal:  J Neurophysiol       Date:  2006-07-26       Impact factor: 2.714

Review 6.  Neuropsychiatric effects of prescription drug abuse.

Authors:  Jason P Caplan; Lucy A Epstein; Davin K Quinn; Jonathan R Stevens; Theodore A Stern
Journal:  Neuropsychol Rev       Date:  2007-08-16       Impact factor: 7.444

7.  Parvalbumin cell ablation of NMDA-R1 causes increased resting network excitability with associated social and self-care deficits.

Authors:  Eddie N Billingslea; Valerie M Tatard-Leitman; Jaynie Anguiano; Catherine R Jutzeler; Jimmy Suh; John A Saunders; Susumu Morita; Robert E Featherstone; Pavel I Ortinski; Michael J Gandal; Robert Lin; Yuling Liang; Raquel E Gur; Gregory C Carlson; Chang-Gyu Hahn; Steven J Siegel
Journal:  Neuropsychopharmacology       Date:  2014-02-14       Impact factor: 7.853

8.  Juvenile exposure to ketamine causes delayed emergence of EEG abnormalities during adulthood in mice.

Authors:  R E Featherstone; L R Nagy; C G Hahn; S J Siegel
Journal:  Drug Alcohol Depend       Date:  2013-09-27       Impact factor: 4.492

9.  Novel environment and GABA agonists alter event-related potentials in N-methyl-D-aspartate NR1 hypomorphic and wild-type mice.

Authors:  Christina L Bodarky; Tobias B Halene; Richard S Ehrlichman; Anamika Banerjee; Rabindranath Ray; Chang-Gyu Hahn; Gerald Jonak; Steven J Siegel
Journal:  J Pharmacol Exp Ther       Date:  2009-07-14       Impact factor: 4.030

10.  Acetyl L-carnitine targets adenosine triphosphate synthase in protecting zebrafish embryos from toxicities induced by verapamil and ketamine: An in vivo assessment.

Authors:  Xiaoqing Guo; Melanie Dumas; Bonnie L Robinson; Syed F Ali; Merle G Paule; Qiang Gu; Jyotshna Kanungo
Journal:  J Appl Toxicol       Date:  2016-05-18       Impact factor: 3.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.